B7-H3在肿瘤生长、耐药性生成及免疫治疗中的研究进展  

Research progress of B7-H3 in tumor growth,drug resistance formation and immunotherapy

作　　者：胡陈睿 赵鑫[1] HU Chenrui;ZHAO Xin(Department of General Surgery,the First Affiliated Hospital of Soochow University,Suzhou 215006,China)

机构地区：[1]苏州大学附属第一医院普外科,苏州215006

出　　处：《中国免疫学杂志》2024年第1期202-207,共6页Chinese Journal of Immunology

基　　金：国家自然科学基金项目(31770985,8273180);姑苏卫生人才培养项目(GSWS2019028)。

摘　　要：B7H3(也称为CD276)是一种新近发现的免疫协同刺激分子,是免疫协同刺激分子B7家族中的一员。由于B7-H3的受体目前还没有被确认,所以有关于其免疫功能以及胞内信号传递的具体作用机制尚未明确。B7-H3在诸多恶性肿瘤中都有着极高的表达,这代表着其不但可以作为诸多恶性肿瘤的肿瘤标志物辅助临床诊断,而且可以作为肿瘤靶向治疗的有效靶点。本篇综述主要介绍协同刺激分子B7-H3发展的历史,在各种恶性肿瘤发生发展与产生抗肿瘤药物的耐药性中可能发挥的作用,以及目前以B7-H3为靶点的治疗手段。B7-H3(also known as CD276)is a newly discovered immune costimulatory molecule and a member of the B7 family of immune costimulatory molecules.Since the receptor of B7-H3 has not been identified yet,the specific mechanism of its immune function and intracellular signal transmission has not yet been clarified.B7-H3 is highly expressed in many malignant tumors,which indicates that not only B7-H3 can be used as a tumor marker for many malignant tumors to assist clinical diagnosis,which can be used as an effective target for tumor targeted therapy.This review mainly introduces the history of the development of the costimulatory mole-cule B7-H3 and its possible role in the development of various malignant tumors and the development of anti-tumor drug resistance,as well as the current mainstream therapeutic approaches targeting B7-H3.

关 键 词：协调刺激分子 B7-H3 恶性肿瘤 肿瘤耐药性 肿瘤靶向治疗 

分 类 号：R392.11[医药卫生—免疫学]